Hypertension in malignancy-an underappreciated problem

Abstract

Hypertension is one of the most common comorbidities in cancer patients with malignancy, in particular, in the elderly. On the other hand, hypertension is a long-term consequence of antineoplastic treatment, including both chemotherapy and targeted agents. Several chemotherapeutics and targeted drugs may be responsible for development or worsening of the hypertension. The most common side effect of anti-VEGF (vascular endothelial growth factor) treatment is hypertension. However, pathogenesis of hypertension in patients receiving this therapy appears to be associated with multiple pathways and is not yet fully understood. Development of hypertension was associated with improved antitumor efficacy in patients treated with anti-antiangiogenic drugs in some but not in all studies. Drugs used commonly as adjuvants such as steroids, erythropoietin stimulating agents etc, may also cause rise in blood pressure or exacerbate preexisiting hypertension. Hypotensive therapy is crucial to manage hypertension during certain antineoplastic treatment. The choice and dose of antihypertensive drugs depend upon the presence of organ dysfunction, comorbidities, and/or adverse effects. In addition, severity of the hypertension and the urgency of blood pressure control should also be taken into consideration. As there are no specific guidelines on the hypertension treatment in cancer patients we should follow the available guidelines to obtain the best possible outcomes and pay the attention to the individualization of the therapy according to the actual situation.

Electrochemical study of gold recovery from ammoniacal thiosulfate, simulating the PCBs leaching of mobile phones

“…In solutions containing copper and thiosulfate in ammoniacal medium is important to note that thiosulfate reacts with copper (II) ions and produces the The diffusion coefficient for solutions containing copper and thiosulfate in ammoniacal medium obtained in this study was 4.9 × 10 -10 m 2 /s. This value is consistent with the values found in the bibliography [54][55][56][57].…”

Hypertension and chronic kidney disease is highly prevalent in elderly patients with colorectal cancer undergoing primary surgery

“…17 The possible associations between CKD, hypertension and malignancy were reviewed recently. 18,19 Attention should also be paid to the limitations of our study, which consisted of a relatively small sample pooled in just 1 center. The population prevalence of hypertension and CKD was not compared with that of the group of patients with CRC.…”

Hypertension management in cardio-oncology

“…This is particularly more profound in patients treated with angiogenesis inhibitors, where rates of hypertension close to 70% have been reported with some therapies [9]. The overall lack of data in prevalence suggests widespread under-diagnosis and undertreatment [10]. Table 1 grades the severity of hypertension occurring secondary to anticancer therapies based on the latest version of US Common Terminology Criteria for Adverse Events [11].…”

“…This is particularly more profound in patients treated with angiogenesis inhibitors, where rates of hypertension close to 70% have been reported with some therapies [ 9 ]. The overall lack of data in prevalence suggests widespread under-diagnosis and undertreatment [ 10 ].…”